2004 | Phase I and Pharmacokinetic study of the oral fluoropyrimidine S-1 on a Once-Daily-for-28-day schedule in patients with advanced malignancies
| CLINICAL CANCER RESEARCH |
1998 | Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS |
2016 | Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma
| ONCOTARGET |
2017 | Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
| ONCOTARGET |
2020 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
| JOURNAL OF CLINICAL ONCOLOGY |
2020 | Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
| CANCERS |
2023 | Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors | TARGETED ONCOLOGY |
2020 | Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2021 | Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy
| STEM CELLS INTERNATIONAL |
2008 | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
2019 | Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma | DIGESTIVE AND LIVER DISEASE |
1994 | Phase Ib clinical trial and pharmacokinetic evaluation of recombinant human granulocyte-macrophage colony stimulating factor(rh GM-CSF LBD-005) in advanced cancer patients with chemotherapy induced myelosuppression
| Journal of the Korean Cancer Association(대한암학회지) |
2022 | Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC) | ANNALS OF ONCOLOGY |
2018 | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
| LUNG CANCER |
2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | CLINICAL CANCER RESEARCH |
2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
2014 | Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer | CANCER IMMUNOLOGY IMMUNOTHERAPY |
2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2014 | Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma | JOURNAL OF CLINICAL ONCOLOGY |